ABSTRACT
INTRODUCTION

43
McArdle disease (glycogen storage disease type V [GSD V]; myophosphorylase deficiency; OMIM® 232600) 44 is a metabolic disorder affecting glycogen degradation in skeletal muscle (14) . It has an estimated 45 prevalence of about 1 in 100,000 people, affecting both sexes equally (10, 25) . The disease is caused by 46 pathogenic mutations in the PYGM gene, which encodes the muscle isoform of glycogen phosphorylase
47
(GP-MM, also known as myophosphorylase) (2, 24). Almost 150 mutations in PYGM gene have been
48
reported to cause McArdle disease (17), with the p.R50X mutation being the most prevalent variant in
49
Caucasian patients which has a frequency above 40% in Italy, Spain and United Kingdom (4, 10, 21) . There is 50 no correlation between phenotype and genotype in McArdle disease as mutations generally cause a 51 complete loss of activity (1, 6, 12, 13, 20, 21) . Muscle glycogen is an important fuel that supports nearly all 52 muscle energy metabolism early in exercise and during high-intensity work (7). Correspondingly, patients 
76
IIA fibers (IIA>IIX,IIB), while in MHC IIB fibers, glucose uptake is mainly contraction-induced through AMPK
77
(IIB>IIA) (11). The four muscles were chosen as they are among the most studied murine muscles and with 78 different fiber type distribution, they represent an oxidative muscle and potentially three different levels of 79 glycolytic activity based on the fiber type distribution spanning from mostly insulin-induced glucose uptake 80 in EDL to mostly contraction-induced glucose uptake in quadriceps, with TA being the intermediate. To
81
address the differential impact of McArdle disease on individual muscles, it was necessary to investigate 82 how glucose metabolism was affected in each muscle by the disorder.
83
In the present study, carbohydrate metabolism in terms of glucose transport, glycolysis, glycogen 84 synthesis and glycogen breakdown in proximal and distal hind limb muscles from adult homozygous 
91
MATERIALS AND METHODS
Animals
93
We 
128
Dura kit (ThermoFisher), quantified using a GBox XT16 darkroom and GeneTools software was used to 129 measure the intensities of immune-reactive bands on 16-bit digital photos (Syngene, Cambridge, UK).
130
Immuno-reactive band intensities were normalized to the intensity of the α-tubulin and GAPDH bands for 
134
were being separated on gels at the same time followed by western blotting.
136
GS Activity Determination.
137
To measure GS activity, muscle samples (100 mg) were homogenized using Mini-BeadBeater-24 (BioSpec
138
Products) in 1 ml of ice-cold homogenization buffer containing 10 mM Tris-HCl(pH 7), 150 mM KF, 15 mM
139
EDTA, 15 mM 2-mercaptoethanol, 0.6 M sucrose, 25 nM okadaic acid, 1mM sodium orthovanadate, 10 140 ug/ml leupeptin, 10 ug/ml aprotinin, 10 ug/ml pepstatin, 1 mM benzamidine, and 1 mM PMSF (Sigma-Aldrich). GS activity was measured in whole homogenates in the absence or presence of 6.6 mM glucose 6- 
161
GLUT4, hexokinase II and fructose 6-P kinase (F6PK), while glycogen synthesis activation was investigated 162 using antibodies against pCaMKII, pGSK3, GS, pGS and the glycogen branching enzyme GBE1. Glycogen 
167
GBE1 (p<0.0004) and PHKA1 (p<0.002) were increased, while pCaMKII (p<0.02) was decreased ( Figure 1D ).
168
This suggests a coherent increase in AMPK-mediated glucose uptake. 
195
Glycogen synthesis is decreased and glycolysis is increased in patients with McArdle disease
196
The glucose/glycogen turnover in specimens of muscle from patients affected by McArdle disease was 197 investigated, and the level of GS and the phosphorylation (inactivation) of GS as well as the branching 198 enzyme GBE1 were found to be significantly higher in patients. The levels of GLUT4, hexokinase II, F6PK
199
were significantly increased in patients (p<0.05), while phosphorylation of AMPK, Akt, TBC1 and TBCD4
200
were not ( Figure 4A ). In the glycogen synthesis pathway, activation of GSK3 was significantly decreased 
261
action in the skeletal muscle of these patients (15) . In this study, pAMPK was not significantly different in
262
McArdle patients, suggesting that increased glucose uptake is not driven by muscle contractions unlike in 
287
PERSPECTIVES AND SIGNIFICANCE 288
The present study clearly demonstrates the large difference in ability to circumvent an energy crisis where 
293
by increasing the ability to take up glucose for direct glycolysis despite the lack of MHC type IIB in humans.
294
The significant difference in metabolic response to glycogen breakdown deficiency among muscles in the
295
McArdle mouse makes this model suitable for studies of the importance of glycogen in various muscles in 296 the mouse and for comparative studies with humans. Future directions include whether the mouse is 297 capable of increasing hepatic glucose output or fatty acid oxidation as observed in humans affected by
298
McArdle disease. It may also be used to give a broader picture of the benefits and potential pitfalls of using 299 mouse models of metabolic myopathies for future treatment studies considering the different metabolic 300 profiles in the hind limb muscles, which may affect interpretation of results.
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